Uvavanyo lwe-COVID emva kwiMbango ePhakamileyo ngenxa ye-Omicron

IsiXeko saseNew York, ngoku esiphinde saba sisibetho sobhubhani e-US, sibhale phantse amatyala amatsha angama-50,000 ngoDisemba 24 kuphela. Olu lolona suku luphezulu lulonke kurhulumente ukusukela oko waqala ubhubhane.

Ngokufanayo nowama-2020, i-spike yelizwe lonke kwiimeko ibe yingozi kuqoqosho ngenxa yezithintelo, eziye zachaphazela iminyhadala yezemidlalo, ukuhambisa ngenqanawa kwaye ngakumbi ukuhamba, amawaka eenqwelomoya arhoxisiwe kwimpelaveki yeholide. Kwihlabathi jikelele, iinqwelomoya zirhoxise ngaphezulu kwe-6,000 yeenqwelomoya ngo-Krisimesi, iKrisimesi kunye nosuku olusemva kweKrisimesi, ngokutsho kweFlightAware. Todos Medical Ltd., Pfizer Inc., Moderna, Inc., Inovio Pharmaceuticals, Inc., Merck & Co., Inc.

Ngokuka-Anthony S. Fauci, umcebisi oyintloko kwezonyango kuMongameli u-Biden, kuya kubaluleka kakhulu, “ukuba sifumane amandla amakhulu ovavanyo, ngakumbi xa imfuno yovavanyo iphezulu kakhulu, kunye nokudityaniswa kokwahluka kwe-Omicron ngokwayo. , kunye nexesha leholide, apho abantu bafuna ukufumana umgangatho owongezelelekileyo wengqiniseko yokuba bakhuselekile, nokuba ugonyiwe kwaye uphuculwe.

I-Todos Medical Ltd ibhengeze izolo ukuba, "i-CLIA/CAP PCR yayo ezenzekelayo kakhulu kunye nelebhu yovavanyo ye-cPass eyenza i-antibody ye-COVID-19 i-Provista Diagnostics izuze irekhodi elandelelanayo yovavanyo lwe-PCR lweveki ngeeveki zikaDisemba 13, 2021 kunye noDisemba 20, 2021. Imiyinge yovavanyo lwe-COVID PCR yayiqhutywa ikakhulu lishishini elebhu yesalathiso evela kwilebhu yovavanyo yePCR esekwe eNew York engakwaziyo ukuzalisekisa imfuno yovavanyo kwindawo yayo. Inkampani iphinde yangena kwisivumelwano esitsha seenkonzo zaselabhoratri kunye nogqirha osekwe eNew Jersey kuvavanyo lwe-COVID PCR kunye novavanyo lwe-COVID cPass.

'Imfuno yovavanyo lwe-PCR ikhula ngokukhawuleza kwiipokethi zase-United States, kwaye silindele ukuba oku kuqhubeke ngaphaya kokunyuka kweeholide njengabantu ngabanye, izikolo kunye nabaqeshi bafuna ukudala iindawo ezikhuselekileyo, ngakumbi kwiindawo ezinamazinga aphantsi okugonywa,' kusho uGerald E. Commissiong, uMongameli kunye ne-CEO ye-Todos Medical, inkampani engumzali ye-Provista Diagnostics. 'Ngenxa yesigunyaziso esisalindelweyo 'sogonyo okanye uvavanyo' oluvela kuLawulo lwe-Biden oluya kuthi lubeke iimfuno zovavanyo kwi-38% yabantu abadala base-US abangekagonyo ngokupheleleyo kwi-COVID-19, sibona ukunqongophala kovavanyo oludityanisiweyo isigunyaziso esilindileyo sokudala imfuno yokonyuka okubaluleke kakhulu kuvavanyo lwe-COVID PCR lwexesha elide lwe-Provista. Xa usongeza isakhono se-Omicron sokuphepha isitofu sokugonya okanye ukugonywa kosulelo, kunye nemiceli mngeni yokufikelela kunye nokuthembeka kovavanyo olukhawulezayo lwe-antigen oluthi luvelise iziphumo ezingezizo ezingezizo, uvavanyo lwe-COVID PCR olukhawulezayo lokujika luvela njengowona mthombo uthembekileyo nothembekileyo. yolwazi lokwazi imeko yomntu yosulelo lwe-COVID.'

UMnu. Commissiong uqhubeke wathi, 'Ngaphezu koko, xa udibanisa ezi nyani kunye nokunyuka kwamva nje kumdla wokukhuthaza ukugonya ugonyo okanye ukugonywa kosulelo olufunyenweyo ngokuchasene ne-Omicron, siqala ukubona ukonyuka okuphawulweyo komdla we-cPass yokungathathi hlangothi uvavanyo lwe-antibody ukubeka iliso. Amanqanaba okujikeleza okuthoba uvavanyo lwe-antibody kunye nokuvumela izigulana ukuba zenze izigqibo ezikhawulezileyo, eziqhutywa yidatha ukuze zithole i-booster shots, ngakumbi xa kunikwa idatha ephumayo ebonisa ukuba i-antibody-titers ephezulu eveliswe kukudubula kwe-booster yamva nje yeyona nto inokwenzeka yokukhusela umntu ngokuchasene ne-Omicron. usulelo.'

Idatha yakutsha nje ephuma kwa-Israel icebisa ukuba i-antibody titers ingathathi hlangothi ekuphenduleni isitofu sokugonya se-Pfizer/BioNTech Comirnaty iqala ukuncipha emva kweenyanga ezi-4 ukusuka kugonyo olupheleleyo, kwaye oko kuthotywa kwe-booster ye-Comirnaty iqala ukuncipha emva kweeveki ezili-10 ukusuka kwi-booster shot. Isithonga sesine (i-"Second Booster") isandul' ukugunyaziswa kwa-Israel kwi-immune-compromised kunye ne-60+, kwaye uphononongo luyaqhubeka ukufumanisa ukuqina kwe-Booster yesiBini kuluntu jikelele.

I-Pfizer Inc. ibhengeze kwiveki ephelileyo ukuba i-US Food and Drug Administration (FDA) igunyazise ukusetyenziswa okungxamisekileyo kwe-PAXLOVID™ (nirmatrelvir [PF-07321332] tablets kunye ne-ritonavir tablets) kunyango lwe-COVID-19 ephakathi ukuya kwimodareyitha kubantu abadala. kunye nezigulana zabantwana (abaneminyaka eli-12 ubudala nangaphezulu abanobunzima obungama-40 kg [88 lbs]) abaneziphumo ezilungileyo zovavanyo oluthe ngqo lwe-SARS-CoV-2 lwentsholongwane, kwaye abasemngciphekweni omkhulu wokuqhubekela phambili kwi-COVID-19 eqatha, kubandakanya nokulaliswa esibhedlele okanye ukufa. Unyango lubandakanya i-nirmatrelvir, inoveli ephambili ye-protease (Mpro) inhibitor evela kwiilabhoratri ze-Pfizer, eyayiyilelwe ngokukodwa ukuvala umsebenzi we-SARS-CoV-2 Mpro, i-enzyme ekufuneka iphindaphindwe yi-coronavirus. "Ugunyaziso lwanamhlanje lwe-PAXLOVID lumele omnye umzekelo omangalisayo wendlela isayensi eya kusinceda ngayo ekugqibeleni soyise lo bhubhani, othi, nokuba yiminyaka emibini uqhubekile, uqhubeleka nokuphazamisa kunye nokutshabalalisa ubomi kwihlabathi liphela. Olu nyango lwempumelelo, olubonakaliswe ukuba lunciphisa kakhulu ukulaliswa esibhedlele kunye nokufa kwaye lunokuthi luthathwe ekhaya, luya kutshintsha indlela esiphatha ngayo i-COVID-19, kwaye ngethemba lokunceda ukunciphisa uxinzelelo olubalulekileyo olujongene nezempilo kunye neenkqubo zesibhedlele, ”utshilo uAlbert. Bourla, uSihlalo kunye neGosa eliLawulayo eliyiNtloko, uPfizer. "I-Pfizer ikulungele ukuqalisa ukuhanjiswa e-US ngokukhawuleza ukunceda ukufumana i-PAXLOVID ezandleni zezigulana ezifanelekileyo ngokukhawuleza."

IModerna, Inc. yabhengezwa nge-20 kaDisemba, idata yokuqala yokuthintela i-antibody ngokuchasene neyantlukwano ye-Omicron ilandela abagqatswa be-booster beNkampani kumanqanaba ethamo le-50 µg kunye ne-100 µg. I-50 µg ye-booster yangoku ye-mRNA-1273 yonyuse amanqanaba e-antibody ngokuchasene ne-Omicron malunga ne-37-fold xa kuthelekiswa namanqanaba okunyusa kwangaphambili kunye ne-100 µg yedosi ye-mRNA-1273 yonyuse amanqanaba e-antibody malunga nama-83 ngokuphindwe xa kuthelekiswa namanqanaba okunyusa kwangaphambili. “Ukonyuka okumangalisayo kwamatyala e-COVID-19 ukusuka kukwahluka kwe-Omicron kubhekiselele kubo bonke. Nangona kunjalo, ezi datha zibonisa ukuba iModerna COVID-19 egunyazisiweyo yangoku inokunyusa amanqanaba e-antibody ngokuphindwe ngama-37 aphezulu kunamanqanaba okunyusa kwangaphambili iyaqinisekisa, utshilo uStéphane Bancel, iGosa eliLawulayo leModerna. "Ukusabela kolu lwahluko lusulela kakhulu, iModerna iya kuqhubeka ngokukhawuleza iqhubela phambili umgqatswa we-Omicron-specific booster kuvavanyo lweklinikhi ukuba kunokwenzeka kwixesha elizayo. Siza kuqhubeka nokuvelisa kunye nokwabelana ngedatha kuzo zonke izicwangciso zethu zokukhuthaza kunye nabasemagunyeni kwezempilo ukuze sibancede benze izigqibo ezisekwe kubungqina kwezona zicwangciso zingcono zokugonya ngokuchasene ne-SARS-CoV-2. "

I-Inovio Pharmaceuticals, Inc. ibhengeze uhlaziyo lwenyanga ephelileyo kwinkqubo yeSigaba sesi-3 se-VGX-3100 ye-HPV enxulumene nomlomo wesibeleko esinezilonda ze-squamous intraepithelial lesions (HSIL), kubandakanywa ukulandelwa konyaka omnye wokuphumelela kunye nedatha yokhuseleko kubathathi-nxaxheba abavela kwi-REVEAL1. , ukugqiba ukubhaliswa kwi-REVEAL2, kunye nokuqhubela phambili umgqatswa we-biomarker wangaphambi konyango we-VGX-3100 ukuba aphuhliswe ngakumbi nge-QIAGEN. Ukongeza, ihlakani lophuhliso le-INOVIO phakathi kwe-Greater China (ilizwe laseTshayina, i-Hong Kong, i-Macao, i-Taiwan), i-ApolloBio Corp. (“i-ApolloBio”), ikhuphe umthathi-nxaxheba wokuqala kulingo olwahlukileyo lweSigaba sesi-3 e-China. UGqr. J. Joseph Kim, uMongameli kunye ne-CEO ye-INOVIO, uthe, “Senza inkqubela phambili emandla ekuphuhliseni i-INOVIO's immunotherapies enyanga i-HPV ehambelana ne-HSIL yomlomo wesibeleko. Xa inganyangwanga, i-HSIL yomlomo wesibeleko inokuqhubeleka ibe ngumhlaza. I-VGX-3100 inamandla okuba yeyona ndlela yokuqala evunyiweyo yokugonywa komzimba kunye neyokungatyandwa kwabasetyhini abane-HSIL yomlomo wesibeleko kwaye sijonge phambili ekuqhubeleni phambili iinzame zethu kwizifundo zethu zeSigaba sesi-3 ngokurhweba.

I-Merck & Co., Inc. ibhengeze ekuqaleni kwale nyanga ukuba i-New England Journal of Medicine ipapashe iziphumo ezivela kwiSigaba se-3 solingo lwe-MOVe-OUT oluvavanya i-molnupiravir, iyeza lophando lonyango lonyango lwe-antiviral, kubantu abadala abangalaliswanga esibhedlele abasemngciphekweni omkhulu abanobuthathaka ukuya phakathi kwe-COVID. -19. Idatha evela kwi-MOVe-OUT ibonise ukuba unyango lwakwangoko nge-molnupiravir luwunciphise kakhulu umngcipheko wokulaliswa esibhedlele okanye wokusweleka kumngcipheko omkhulu, abantu abadala abangagonywanga abane-COVID-19. I-Merck iphuhlisa i-molnupiravir ngentsebenziswano ne-Ridgeback Biotherapeutics. I-Molnupiravir igunyaziswe e-United Kingdom njengeye-antiviral yokuqala yomlomo yonyango lwe-COVID-19 ephakathi ukuya kwephakathi kwabantu abadala abanovavanyo lokuxilongwa oluqinisekileyo lwe-SARS-CoV-2 kwaye abanomngcipheko omnye ubuncinane wokukhula kwesigulo esiqatha. I-Arhente yaMayeza yaseYurophu (EMA) ikhuphe uluvo lwezenzululwazi oluncomekayo lwe-molnupiravir phantsi kweSiqendu 5.3 soMmiselo 726/2004, enjongo yawo ikukuxhasa ukuthathwa kwezigqibo kuzwelonke malunga nokusetyenziswa okunokwenzeka kwe-molnupiravir phambi kogunyaziso lwentengiso. Izicelo zolawulo ziphantsi koqwalaselo okanye zisendleleni yokungeniswa, kubandakanywa izicelo zoGunyaziso lokuSebenzisa oluNgxamisekileyo (EUA) yi-US Food and Drug Administration (FDA) kunye noMphathiswa wezeMpilo waseJapan, uMsebenzi kunye neNtlalontle.